Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers.
Although constituting only 1% of all human malignancies, sarcomas represent the second …

Sarcomas are complex mesenchymal neoplasms with a poor prognosis. Their clinical
management is highly challenging due to their heterogeneity and insensitivity to current …

Simple Summary Chondrosarcoma (CHS) belongs to a broad group of sarcomas and is the
second most frequent malignant bone tumor. Due to its resistance to chemo-and …

Bone and soft tissue sarcomas account for approximately 15% of pediatric solid malignant
tumors and 1% of adult solid malignant tumors. There are over 50 subtypes of sarcomas …

Recent clinical trials have shown several multi-target tyrosine kinase inhibitors (TKIs) to be
effective in the treatment of osteosarcoma. However, these TKIs have a number of targets …

When dysregulated, skin fibrosis can lead to a multitude of pathologies. We provide a
framework for understanding the wide clinical spectrum, mechanisms, and management of …

Background Previous studies have demonstrated the efficacy of apatinib and anlotinib for
the treatment of sarcomas. However, more clinical data and evidence are needed to support …

Apatinib is a multitarget tyrosine kinase inhibitor marketed in China for the treatment of
advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It has also been used …

Sarcomas are a heterogeneous group of rare malignancies originating from mesenchymal
tissues with limited therapeutic options. Recently, alterations in components of the fibroblast …

Kinase inhibitors (KIs) are important cancer drugs but often feature polypharmacology that is
molecularly not understood. This disconnect is particularly apparent in cancer entities such …